{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Non-squamous+Non+Small+Cell+Lung+Cancer&page=5", "query": { "condition": "Metastatic Non-squamous Non Small Cell Lung Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 324, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Non-squamous+Non+Small+Cell+Lung+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Non-squamous+Non+Small+Cell+Lung+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T04:44:38.117Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06627647", "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1160, "start_date": "2024-11-27", "completion_date": "2030-11-18", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 78, "location_summary": "Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06627647" }, { "nct_id": "NCT04033354", "title": "A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Non Small Cell Lung Cancer" ], "interventions": [ { "name": "HLX10", "type": "DRUG" }, { "name": "carboplatin and nab paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Henlius Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 537, "start_date": "2019-08-14", "completion_date": "2023-12-30", "has_results": false, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 1, "location_summary": "Roanoke, Virginia", "locations": [ { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04033354" }, { "nct_id": "NCT01976741", "title": "Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Rogaratinib (BAY1163877) oral solution", "type": "DRUG" }, { "name": "Rogaratinib (BAY1163877) oral tablet", "type": "DRUG" }, { "name": "Rogaratinib (BAY1163877) 800 mg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2013-12-30", "completion_date": "2020-01-09", "has_results": true, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 3, "location_summary": "Chicago, Illinois • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01976741" }, { "nct_id": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Other Solid Tumors", "Diffuse Large B-cell Lymphoma (DLBCL)", "Mantle Cell Lymphoma", "Indolent B-cell Lymphomas", "Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Waldenstrom's Disease", "Marginal Zone Lymphoma", "Mucosa Associated Lymphoid Tissue", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "CDX-1140", "type": "DRUG" }, { "name": "CDX-301", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2017-12-01", "completion_date": "2022-09-13", "has_results": false, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329950" }, { "nct_id": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Malignant Solid Tumors" ], "interventions": [ { "name": "enfortumab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2020-03-10", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 29, "location_summary": "Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04225117" }, { "nct_id": "NCT01837329", "title": "Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Tetrathiomolybdate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2013-11", "completion_date": "2019-01-11", "has_results": false, "last_update_posted_date": "2019-07-19", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01837329" }, { "nct_id": "NCT06799065", "title": "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Breast Cancer Recurrent", "Ovarian Cancer", "High-grade Serous Ovarian Carcinoma", "Triple Negative Breast Cancer", "sqNSCLC", "Squamous Non-small-cell Lung Cancer" ], "interventions": [ { "name": "ATX-295", "type": "DRUG" }, { "name": "ATX-295 and bevacizumab (or biosimilar)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accent Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2025-03-21", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 11, "location_summary": "Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799065" }, { "nct_id": "NCT05077709", "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer Non Small Cell", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma Bladder" ], "interventions": [ { "name": "IO102-IO103 in combination with pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IO Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2022-04-11", "completion_date": "2026-02-08", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 9, "location_summary": "Duarte, California • Sacramento, California • San Diego, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Orange City", "state": "Florida" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077709" }, { "nct_id": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer", "Head and Neck Cancer", "Melanoma", "Gastric Cancer", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Resectable Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "INBRX-106 - Hexavalent OX40 agonist antibody", "type": "DRUG" }, { "name": "pembrolizumab 200 mg", "type": "DRUG" }, { "name": "pembrolizumab 400 mg", "type": "DRUG" }, { "name": "Carboplatin AUC-5", "type": "DRUG" }, { "name": "Carboplatin AUC-6", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m2", "type": "DRUG" }, { "name": "Cisplatin 75mg/m2", "type": "DRUG" }, { "name": "Paclitaxel 200mg/m2", "type": "DRUG" }, { "name": "Nab paclitaxel 100mg/m2", "type": "DRUG" }, { "name": "Gemcitabine (1000 mg/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2019-12-10", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 30, "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198766" }, { "nct_id": "NCT00227019", "title": "Phase 2 Trial of Bevacizumab in Combination With Pemetrexed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)", "Lung Cancer", "Neoplasm Metastasis" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Vitamin B12", "type": "DRUG" }, { "name": "Folate", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Heather Wakelee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2006-03", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-10-12T04:44:38.117Z", "location_count": 4, "location_summary": "Stanford, California • Lebanon, New Hampshire • Voorhees Township, New Jersey + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Voorhees Township", "state": "New Jersey" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00227019" } ] }